Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

753
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
753

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study.

Cancers·2026
Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026
Same author

Low-dose Empagliflozin Does Not Modify Myocardial Energetics and Function in a Large-animal Model of Hibernating Myocardium.

Journal of cardiovascular translational research·2026
Same author

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

The American journal of clinical nutrition·2026
Same author

Growing with the patient: toward a lifespan risk score for pediatric pulmonary hypertension.

Revista espanola de cardiologia (English ed.)·2026
Same author

Mapping Echocardiographic Practice in Emilia-Romagna: A Regional Healthcare Census.

Journal of clinical medicine·2026

相关实验视频

Updated: Sep 9, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

在心肌梗塞后不减少喷射分数的β- 阻塞剂

Borja Ibanez1,2,3, Roberto Latini4, Xavier Rossello1,3,5,6

  • 1Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid.

The New England journal of medicine
|September 1, 2025
PubMed
概括

治疗β阻塞剂对心肌梗塞后的患者没有显著的益处. 这项研究没有发现死亡,心脏病复发或心力衰竭住院率的差异.

更多相关视频

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

相关实验视频

Last Updated: Sep 9, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

科学领域:

  • 心脏病学
  • 临床试验
  • 药理学

背景情况:

  • 目前针对心肌梗塞 (MI) 后的β- 阻断剂的指导方针是基于现代治疗之前的较旧试验数据.
  • 当代护理包括常规的再输血,侵入性策略和先进的药物治疗,需要更新证据.
  • 根据目前的治疗模式,贝塔阻塞剂在心脏病发作中保持射出分数 (LVEF> 40%) 的作用仍然不确定.

研究的目的:

  • 在急性心脏病发作患者中,评估β- 阻断剂治疗与不使用β- 阻断剂治疗的疗效> 40%.
  • 评估β抑制剂对该特定患者群体主要心血管不良事件的影响.
  • 为当代心脏病治疗中使用β- 阻断剂提供基于证据的建议.

主要方法:

  • 在西班牙和意大利进行的开放式随机试验.
  • 8438名急性心脏病发作和LVEF> 40%的患者被随机分配给β- 阻断剂治疗或没有β- 阻断剂治疗.
  • 主要结局:综合所有死因,心脏衰竭再发作或住院治疗,随访时间中位数为3. 7年.

主要成果:

  • 在β抑制剂组 (22.5事件/1000患者年) 和无β抑制剂组 (21. 7事件/1000患者年) 之间,主要结论没有显著差异;危险比率 (HR) 为1. 04,P=0. 63.
  • 主要结局的各个组成部分 (全因死亡,再发作,心力衰竭住院) 也没有显著的组间差异.
  • 治疗组之间没有明显的安全结果差异.

结论:

  • 在接受入侵治疗的LVEF> 40% 的心脏病发作后患者中,β- 阻断剂治疗对死亡,再发作或心力衰竭住院的综合结果没有显著影响.
  • 这些发现表明,当前针对这种特定MI亚组的β阻断剂的指导建议可能需要重新评估.
  • 这项研究由国家心血管研究中心卡洛斯三世等资助;NCT03596385.